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Summary  
To determine the safety and efficacy of viscosupplementation with hylan G-F 20, a cross-linked hyaluronan preparation, 
used either alone or in combination with continuous non-steroidal anti-inflammatory drug (NSAID) therapy, a
randomized, controlled, multicenter clinical trial, assessed by a blinded assessor, was conducted in 102 patients with 
osteoarthritis (OA) of the knee. All patients were on continuous NSAID therapy for at least 30 days prior to entering the 
study. Patients were randomized into three parallel groups: (1) NSAID continuation plus three control arthrocenteses 
at weekly intervals; (2) NSAID discontinuation but wi h three weekly intra-articutar injections of hylan G-F 20; and (3) 
NSAID continuation plus three injections, one every week, intra-articular injections of hylan G-F 20. Outcome measures 
of pain and joint function were evaluated by both the patients and an evaluator at baseline and weeks 1, 2, 3, 7 and 12, 
with a follow-up telephone valuation at 26 weeks. At 12 weeks all groups howed statistically significant improvements 
from baseline, but did not differ from each other. A statistical test for equivalence, the q-statistic, demonstrated that 
viscosupplementation with hylan G-F 20 was at least as good or better than continuous NSAID therapy for all outcome 
measurements except activity restriction. At 26 weeks both groups receiving hylan G-F 20 were significantly better than 
the group receiving NSAIDs alone. A transient local reaction was observed in three patients after hylan G-F 20 inj ection; 
only one patient withdrew from the study as a result and all recovered without any sequela. 
Hylan G-F 20 is a safe and effective treatment for OA of the knee and can be used either as a replacement for or an 
adjunct o NSAID therapy. 
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In t roduct ion  
OSTEOARTHRITIS (OA) is common and costly [1, 2]. 
OA affecting the knee is especially troublesome. 
While OA i s  character ized pathological ly by 
deter iorat ion and loss of the art icular  carti lage, 
subchondral  sclerosis and osteophyte formation, 
and is often accompanied by inf lammation of the 
synovium, deter iorat ion of the support ing struc- 
tures of the joint and a mult i tude of other 
pathological  features [3-5], it is mainly pain and loss 
of funct ion that  lead patients with OA to seek 
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medical attent ion [6]. At present, no medical or 
physical therapy has been shown convincingly to 
affect the rate of the deter iorat ion of the affected 
joint structures in humans, so therapeut ic  efforts 
are r ightly directed to symptomatic  rel ief of pain 
arid attempts to preserve joint function. Many  types 
of t reatment  have a role in the management  of the 
pain of OA. These include symptomatic pharmaco-  
logical t reatment with analgesics, non-steroidal  
ant i - inf lammatory drugs (NSAIDs) and intra-art icu- 
lar cort icosteroid injections, muscle s t rengthening 
exercises, weight loss, the use of devices, such as 
canes and orthotics, arthroscopic jo int debride- 
ment, jo int lavage, total  joint replacement,  edu- 
cat ion and counsel ing [7, 8]. 
While analgesics may be as effective as NSAIDs in 
treat ing some patients with OA of the knee [9, 10], 
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NSAIDs are considered a standard treatment for 
OA. Unfortunately, many patients either cannot 
tolerate NSAIDs or suffer serious NSAID-induced 
side-effects, predominantly gastrointestinal ulcera- 
tion and bleeding [11-14]. The frequency of 
NSAID-associated side effects has led to the use 
of cytoprotective agents to improve their safety 
profile [15-17]. Within this context, a re-evaluation 
of the role of NSAIDs in the overall management of 
OA seems appropriate. 
It has been known for many years that synovial 
fluid from osteoarthritic joints is lower in elasticity 
and viscosity than that from normal joints [18, 19]. 
This decrease in the rheological properties of the 
synovial fluid results from reductions in the 
molecular size and concentration of hyaluronan 
in the synovial fluid [19]. This phenomenon led 
Balazs to introduce viscosupplementation therapy 
[20], which is the injection of hyaluronan or its 
derivatives in an attempt to return the elasticity and 
viscosity of the synovial fluid to normal or higher 
levels [21]. While viscosupplementation with 
hyaluronan is not 'mainstream' therapy for OA of 
the knee in North American clinical practice, it has 
been used extensively elsewhere, especially in Italy 
and Japan, and has been the subject of numerous 
clinical trials (reviewed in [22]). From that 
experience, viscosupplementation with hyaluronan 
has been shown• to be a safe treatment of OA of the 
knee, although six to 10 injections are often 
required to achieve efficacy [22]. Possible reasons 
why so many injections are required are that the 
elastoviscous properties of current hyaluronan 
preparations are inadequate to restore sufficiently 
the elasticity and viscosity of the synovial fluid in 
the arthritic knee, or that the injected hyaluronan 
is eliminated too quickly from the joint to be 
effective. Both of these mechanisms depend upon the 
rheological properties of the hyaluronan, which in 
turn depend upon its molecular weight. The results 
of viscosupplementation therapy might therefore 
be expected to depend upon the rheological 
properties and molecular weight of the hyaluronan 
preparation [23]. 
Because of this limitation in viscosupplemen- 
tation with hyaluronan preparations, hylans 
(chemically cross-linked hyaluronans) were devel- 
oped to improve the efficacy of viscosupplementa- 
tion therapy of OA [24]. Cross-linking hyaluronan 
improves its util ity for viscosupplementation n 
several ways. First, the rheological properties are 
increased [25]; second, it has a longer etention time 
in the synovial space [24]; and third, because of the 
cross-links, it becomes more resistant to free radical 
degradation [26]. One particular combination of 
hylans, hytan G-F 20 (Synvisc~), has been developed 
specifically as a device for viscosupplementation 
therapy in OA of the knee. 
Initial studies have shown that injections of hylan 
G-F 20 are safe and effective [27]. In a double-blind 
controlled study involving 50 patients, two injec- 
tions of hylan G-F 20 administered 2 weeks apart 
were shown to be effective in relieving the pain of 
OA of the knee [27]. In a similar study involving 30 
patients, a treatment regimen consisting of three 
injections of hylan G-F 20 given 1 week apart was 
significantly better than saline injections, and gave 
more pain relief than the two-injection regimen 
from the previous study [27]. The efficacy of a 
• therapeutic regimen of three weekly injections of 
hylan G-F 20 was further demonstrated in a 
randomized, double-blind, controlled clinical trial 
with 118 patients. In many of the patients the 
beneficial results were maintained for as long as 26 
weeks [28]. Thus, hylan G-F 20 has been shown to be 
significantly more effective than saline injections in 
three randomized ouble-blind trials. Additional 
safety data was accumulated in an open-label trial 
involving 221 patients. In all four of these trials, for a 
total 1028 injections, there were only 17 possibly- 
related adverse reactions, all of which were local 
and transient. Thus, hylan G-F 20 appears to be an 
effective and safe treatment for OA of the knee. (For 
a review see [28].) 
Clearly, if it is appropriate to re-evaluate the role 
of NSAIDs in the therapy of OA, then the role of 
hylan G-F 20 must be evaluated with respect o its 
role in concomitant or separate treatment of OA 
with NSAIDs. To accomplish this, a three-arm 
multicenter, andomized, blinded clinical trial was 
performed. The purpose of the study was.to evaluate 
the safety and effectiveness of three weekly intra- 
articular injections of hylan G-F 20 in an affected 
knee in patients with OA of the knee and to compare 
this treatment with that of continuous oral NSAID 
therapy in both the presence and absence of hylan 
G-F 20 viscosupplementation. 
Mater ia ls  and methods  
PAT IENTS 
Inclusion criteria 
The patients had to be men or women aged 18-75 
years with a diagnosis of chronic idiopathic 
OA of the knee on radiographic examination. A 
Kellgren-Lawrence radiographical grade of I or 2 or 
3 in no more than two compartments (and not a 
grade 3 in the patellofemoral compartment) was 
required [29]. In addition, patients had to satisfy 
at least four of the following six criteria: (1) 
erythrocyte sedimentation rate <30mm/h; (2) 
rheumatoid factor titer <1:160; (3) morning 
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stiffness not longer than 30 min; (4) crepitus on 
active motion; (5) tenderness of the bony margins; 
and (6) physician determination of absence of 
rheumatoid isease. Furthermore, they needed to 
have been tolerant of NSAID treatment for at 
least the 30-day period preceding the trial without 
significant side effects, to have been using the joint 
actively on a daily basis and to have a score of 
> 50 mm on a 100 mm visual analog scale (VAS) for 
pain on motion with weight-bearing, which was the 
primary efficacy variable. The study protocol also 
allowed for any patient who suffered sufficient pain 
in both knees to be treated in both knees, with only 
the most painful knee to be considered to be enrolled 
in the study and evaluated as to efficacy criteria, 
while both knees were evaluated for safety. 
Exclusion criteria 
Patients were excluded if they had any other 
serious systemic disease, depression, or neuroses, 
acute synovitis or excessive ffusion, were clinically 
obese (>30% above normal body weight), had a 
varus or valgus deformity of > 15 ° (as measured on 
the radiograph), were pregnant or not using an 
effective form of contraception (if of child-bearing 
potential), were on chronic daily steroid therapy, or 
had surgery or a joint injection within the previous 
3 months. 
TRIAL DESIGN 
The study was 12 weeks in duration, with a 
fo l low-up telephone interview at 26 weeks. The 
schedule of treatments and visits is shown as a time 
line in Fig. 1. Patients eligible for the study were 
randomly assigned to one of three treatment groups. 
One treatment group (NSAID-only) received a series 
of three weekly arthrocenteses and was instructed 
to continue taking their usual NSAID for the 
duration of the study. A second treatment group 
(hylan G-F 20-only)d iscont inued their usual 
NSAID, but instead received three weekly intra- 
art icular injections of 2.0 ml of hylan G-F 20. The 
third treatment group (hylan G-F 20+NSAID) 
continued their usual NSAID therapy and received 
three weekly 2.0ml intra-articular injections of 
hylan G-F 20. No placebo group was included 
because of ethical constraints and because the goal 
of the study was to compare the efficacy of hylan 
G-F 20 with an established therapeutic modality. 
Furthermore, the efficacy of hylan vs placebo had 
been established in the prior clinical trials [28]. All 
patients were instructed that if the pain became 
unbearable they could take acetaminophen as 
'rescue' analgesia nd were to report the usage of 
their medication to the evaluator at the next 
follow-up visit. All patients were also instructed 
that for the duration of the study they were not to 
receive any additional medication, i.e. no steroids, 
NSAID other than their usual one (if in the first or 
third treatment group) and, no analgesic other than 
acetaminophen. The extent of acetaminophen usage 
was documented using weekly diaries completed by 
the patients and collected by the investigators. 
Patients in the hylan G-F 20-only group may have 
been able to surmise their group assignment from 
their instruction to discontinue NSAID therapy. If 
this incomplete blinding introduced a bias, it would 
beaga ins t  the hylan G-F 20-only group in that 
patients recognized that they were discontinuing 
an active medication, and consequently may have 
expected their condition to worsen. 
Patients were initially seen and evaluated for 
suitability 1 week before treatment initiation. 
Patients were evaluated prior to the injections of 
the week 1 (baseline), 2 and 3 visits and at 
post-treatment weeks 7 and 12. After 12 weeks the 
patients were not specifically instructed with 
respect to NSAID therapy. To obtain data regarding 
the duration of action of hylan G-F 20, the patients 
were contacted by a telephone interview at 
post-treatment week 26, and were requested by the 
evaluator to rate, as if it were on a VAS the same 
variables that had been evaluated by the patients in 
the previous tudy visits and to evaluate the ordinal 
variables. They were also queried concerning 
NSAID use and any other treatments ofOA. Finally, 
they were asked if their pain had returned to 
pre-study level between weeks 12 and 26. 
Patients receiving hylan G-F 20 treatment were 
injected intra-articularly with 2.0 ml of hylan G-F 20 
at each visit for three consecutive weeks (weeks 1, 
2 and 3). Any effusion present in the joint was 
withdrawn prior to treatment. For the patients 
Week 0 1 2 3 4 5 6 7 8 9 10 11 12 26 
Visit 1 2 3 4 5 6 
Evaluation b b ~ ~ b ~ b 
Arthrocentesis ~ ~ ~ Phone 
NSAID 4 Continuous --
FIG. 1. Flow chart of the study procedures. NSAID, non-steroidal nti-inflammatory drug. 
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in the NSAID-only group, the needle of the 
syringe was inserted intra-articularly, any effusion 
present in the joint was withdrawn, but nothing was 
injected. To insure that blinding was maintained, a 
screen was provided so that the patient could 
not observe the treatment. Furthermore, the 
evaluator, who was unaware of each patient's 
treatment group, was not to be present at the time 
or place of each weekly injection. 
OUTCOME MEASURES 
Efficacy 
Each of the following efficacy variables was 
measured at all evaluation visits using a 100 mm 
VAS [30]: pain on motion with weight-bearing; pain 
at rest; pain at night; restriction of activity; patient's 
overall assessment ofarthrit ic pain; pain during a 50 
foot walk; medial joint tenderness; lateral joint 
tenderness; and evaluator's overall assessment of 
the treatment. Pain on motion with weight-bearing 
was the primary efficacy variable. Efficacy variables 
that were measured on an ordinal scale (1 = never 
able to perform; 2 = occasionally able to perform, 
and 3 = frequently able to perform) were the level of 
activity for each of standing, sitting, walking and 
climbing stairs. The severity of the patient's 
pain was also rated categorically by the patient at 
baseline and at post-treatment weeks 1, 2, 3, 7 and 12 
as; 1 = none; 2 = pain only on starting the activity 
after rest; 3=pain during the day when active; 
4 = pain during the day, at rest; or 5 = pain all day and 
waking the patient at night. For all analyses 
which were compared to baseline, the measure- 
ments taken immediately before treatment at week 
1 were considered to be the baseline. 
Safety 
Data regarding safety and adverse events were 
obtained by interviewing the patients at each study 
visit as to any adverse vent experienced since the 
previous visit. The investigator was also instructed 
as to the criteria for identifying whether an adverse 
event was to be considered as treatment related. 
All adverse events were to be reported on the 
appropriate patient assessment of pain as an 
indication of success. Study sites and participating 
personnel were instructed uniformly as to the 
manner in which the study should be conducted 
according to Good Clinical Practice (GCP) guide- 
lines [31, 32], including the completion of the 
patient informed consent form, a review of the study 
protocol and the manner in which patient case 
report forms were to be completed. 
STATISTICAL ANALYSIS 
Sample size was determined using a criterion of 
a 25% improvement in the patient's or evaluator's 
global assessment of pain as an indication of 
success. Based on this, 80% of the two active 
treatment groups (hylan G-F 20, alone or with 
NSAID), as compared to a projected 50% of the 
'control' group (NSAID alone), were expected 
to show success. Sample size was then to be 
based on a comparison of the three treatment 
groups, using a significance level of P = 0.05 and a 
power of 0.80. Thus, the planned sample size was 26 
patients per treatment group, or a total of 78 
• patients. 
Efficacy was analyzed both for the 'evaluable' 
patient population, i.e. limited to those patients 
fulfilling all inclusion and exclusion criteria 
and receiving a full course of three hylan G-F 20 
injections and for the 'intent-to-treat' patient 
population, i.e. including any patient receiving at 
least one arthrocentesis (NSAID-only group) or one 
hylan G-F 20 injection. With respect to efficacy 
analyses, this report focused on the 'evaluable' 
patient population, making reference to the 
'intent-to-treat' patient population only where 
relevant differences occur. With respect o safety 
analysis, this report focused on the 'intent-to-treat' 
patient population, so as to capture data for any 
patient exposed to the test device. 
Data to be analyzed were entered from the 
case report forms into a database and subjected 
to quality assurance procedures that were double 
verified and corrected. Improvements from baseline 
were calculated for individual patients. The 
baseline used for all calculations of improvement 
was the score obtained at week 1 just prior to the 
first intra-articular t eatment. 
Categorical analyses were performed for each 
outcome measure, defining improvement to a VAS 
score below 20 mm as a symptom-free score, in order 
to analyze the difference between the treatment 
groups with respect o the percentage of symptom- 
free patients at 26 weeks. 
Analysis of variance (ANOVA) was used for 
analysis of continuous data and comparisons among 
the three treatment groups. Fisher's LSD multiple 
comparisons test was used to distinguish between 
individual treatments. Paired t-tests were used 
to evaluate efficacy by comparing pre-treatment 
values with post-treatment observations. The 
chi-squared test and tests of proportions were used 
to analyze the categorical data. For the severity of 
pain variable, which did not follow a continuous 
distribution, ANOVA of ranked data was used. Least 
squares means were calculated from the individual 
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patient improvements and used for comparisons 
among the three treatment groups. All analyses 
were performed using SAS software (SAS Institute, 
Cary, NC, U.S.A.). ANOVA was obtained using 
PROC GLM, with the exception of the binomial 
approximation to the normal distribution (Z 
statistic) using categorical analysis tables [33]. 
The so-called q-statistical nalysis [34] was used to 
evaluate whether or not this study could detect a 
difference among the treatments (i.e. to evaluate the 
probability of a type II error). The q-statistical 
analysis is a one-tailed test against the null 
hypothesis that the test treatment is inferior to 
the active control treatment. The q-statistic is the 
ratio of the mean improvement ofthe test treatment 
to the control treatment, and the ql-statistic is the 
ratio of the lower 95% confidence limit of the 
improvement from baseline of the test treatment 
to the improvement from baseline of control 
treatment. In general, studies of adequate size that 
are assessing treatments with similar effects, the 
ql-values are 0.60 or above. In other words, there is 
a 95% confidence that the test treatment is at least 
60% as effective as the control [34]. For this study the 
test group was the hylan G-F 20 only group and the 
control group was the NSAID-only group. The mean 
square error and least-squares means were calcu- 
lated from the ANOVA model to produce ql, the lower 
95% confidence limit of this ratio. 
Resu l ts  
PATIENTS 
Demographic features 
One hundred and two patients entered the trial 
and received at least one arthrocentesis or injection 
of hylan G-F 20 (the 'intent-to-treat' patient 
population). Ninety-three patients completed all 
three intra-articular treatments and complied 
with all elements of the protocol (the 'evaluable' 
patient population); 32 in the NSAID group, 
28 in the hylan G-F 20 group and 33 in the hylan G-F 
20 + NSAID group. Eighty-nine of the 93 evaluable 
patients completed the week 12 follow-up assess- 
ment and 90 completed the week 26 telephone 
interview. In general, the conclusions drawn from 
data for both populations were the same. 
The demographic characteristics of the 'intent-to- 
treat' patient population (the entire study popu- 
lation) are presented in Table I(a); there are no 
significant differences between the treatment 
groups. The duration of disease and X-ray grade 
for the 'intent-to-treat' patient population are 
presented in Table I(b). With respect o duration 
of disease, a statistically significant difference 
was found favoring the two hylan G-F 20 groups. 
Disease duration did not correlate with clinical 
symptoms [35], and the three groups are very similar 
with respect to their baseline scores on efficacy 
outcome measures (see below). Sixteen of the 
patients had only grade i radiological changes, but 
they all had VAS scores > 50 mm for pain on motion 
at baseline (mean 64.1 +_ 2.4) for pain on motion. 
Thus, these patients almost certainly had OA [36]. 
Thirteen patients were treated bilaterally, but 
efficacy was assessed only on the more severely 
affected knee, while safety was assessed on both 
injected knees. 
Ef f i cacy  
BASEL INE  DATA 
Baseline scores for all outcome measures used 
in the analysis of efficacy are show in Table II. 
Statistically significant differences between the 
treatment groups were only found for pain at 
night and support used. The baseline scores 
i l lus t rate  the clinical symptoms of the study 
population. Patient evaluations of pain on motion, 
restriction of activity and overall pain were 
consistently above an average VAS score of 50 
[Table II(a)]. The measurement of severity of pain 
showed mean values between 3 and 4 at baseline, 
indicating an intensity between pain during the day 
when active and pain during the day at rest. The 
measurement of level of activity/running showed 
mean values between 2 and 3 for all three groups, 
indicating an activity level between occasionally 
able to run and never able to run. All other level of 
activity measurements (standing, sitting, walking 
and climbing) were always below a mean ordinal 
score of 2, indicating that most patients were 
occasionally, and some frequently, capable of these 
activities. Evaluator assessments [Table II(b)] 
revealed a similar degree of symptoms, with only 
pain on walking, which was an inclusion criterion, 
and overall clinical assessment having mean 
baseline scores > 50 mm on the VAS. 
Most patients were not  inhibited from the 
Performance of everyday activities, thus the scores 
for the levels of activity were already so low that no 
change could be measured, and this limited their 
usefulness, i.e. they were insensitive to change. 
Furthermore, the baseline VAS scores were 
generally relatively higher than the measures using 
an ordinal scoring system, and so a change in their 
level with the treatments could be measured. The 
useful outcome measures of the study were the 
scores for pain with motion, pain at rest, pain at 
night, restriction of activity and overall evaluation 
of arthrit ic pain rated by the patient using the VAS 
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Table I(a) 
Demographic data summary for the intent-to-treat patient population 
Population 
Hylan G-F 20 
NSAID Hylan G-F 20 +NSAID Total 
Parameter N= 34 N= 31 N= 37 N= 102 
Sex 
Male 11 (32%) 10 (32%) 15 (41%) 36 (35%) 
Female 23 (68%) 21 (68%) 22 (59%) 66 (65%) 
Age at treatment (years) 
Mean ± S.E.M. 63 ± 2 61 ± 2 60 ± 2 61 ___ 1 
Median 64 62 63 63 
Range 37-76 35-74 38-75 35-76 
Height (in) 
Mean ± S.E.M. 68 ± 0.6 65 +_0.6 67 ± 0.8 66 ± 0.4 
Median 65 64 66 65 
Range 60-73 59-75 57--77 57-77 
Weight (lb) 
Mean ± S.E.M. 156 ± 4 162 ± 5 164 ± 6 160 ± 3 
Median 158 166 161 160 
Range 118-196 120-250 107--262 107-262 
There were no significant differences among the roups. NSAID, non-steroidal 
anti-inflammatory drug. 
Table I(b) 
Disease characteristics at baseline as mean in years ± S.E. and 
radiographical grade as number of patients in each grade and the 
percentage of the total group at baseline for the 'intent-to-treat'patient 
population 
Population 
Hylan G-F 20+ 
NSAID Hylan G-F 20 NSAID Total 
Parameter N= 34 N= 31 N= 37 N= 102 
Duration of joint desease 
Mean ± S.E. 8 ± 1" 
X-ray grade (compartment) 
5 ± 0.8 5 ± 0.6 6 ± 0.6 
Medial 
1 11 (32%) 8 (27%) 8 (22%) 27 (27%) 
2 17 (50%) 14 (47%) 17 (47%) 48 (48%) 
3 6 (18%) 8 (27%) 11 (31%) 25 (25%) 
Lateral 
1 20 (61%) 13 (46%) 22 (71%) 55 (60%) 
2 10 (30%) 12 (43%) 8 (26%) 30 (32%) 
3 3 (9%) 3 (11%) 1 (3%) 7 (8%) 
Patellofemoral 
1 18 (56%) 14 (45%) 25 (71%) 57 (58%) 
2 14 (44%) 17 (55%) 10 (29%) 41 (42%) 
3 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
*Indicates the only statistically significant difference among these groups: 
disease duration was longer for the NSAID-only group than for either of the hylan G-F 
20- treated groups (P= 0.025). NSAID, non-steroidal anti-inflammatory drug. 
and the scores for medial joint tenderness, lateral 
joint tenderness, pain while walking and overall 
assessment of clinical condit ion rated by  the 
evaluator on the VAS. 
EFFICACY VS. BASELINE 
Table III(a) presents the mean improvement 
scores at Week 12 for each of the key outcome 
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Table II(a) 
Scores of the outcome measures at baseline--outcome easures evaluated by the patients. The numbers are the raw 
bisual analog scale numbers ± S.E. The P values are for the intergroup comparisons 
Outcome measure 
P-value 
Hylan 
Hylan G-F 20 
Hylan Hylan G-F 20+ +NSAID 
Hylan G-F 20+ G-F 20 NSAID vs 
NSAID G-F 20 NSAID vs vs hylan 
(N= 33) (N= 29) (N= 34) NSAID NSAID G-F 20 
Pain with motion 63 +_ 3 61 ± 3 60 ± 3 NS NS 
Pain with rest 29 ± 4 36 ± 4 26 ± 4 NS NS 
Pain at night 34 ± 5 35 + 5 20 ± 5 NS 0.048 
Severity of pain 3.3 _ 0.2 3.3 + 0.2 3.1 ± 0.2 NS NS 
Restriction of activity 60 ± 4 53 ± 5 51 ± 4 NS NS 
Overall assessment of arthritic pain 62 ± 3 62 ± 3 57 ± 3 NS NS 
Support used 1.4 ± 0.08 1.1 ± 0.09 1.1 ± 0.08 0.022 NS 
Standing/walking 
Level of activity (standing) 1.2 ± 0.06 1.1 ± 0.07 1.1 ± 0.06 NS NS 
Level of activity (sitting) 1.2 ± 0.08 1.4 ± 0.09 124 ± 0.08 NS NS 
Level of activity (walking) 1.2 ± 0.08 1.4 ± 0.08 1.2 ± 0.08 NS NS 
Level of activity (climbing) 1.7 ± 0.1 1.5 ± 0.1 1.5 ± 0.1 NS NS 
Level of activity (running) 2.7 ± 0.08 2.8 ± 0.09 2.6 ± 0.08 NS NS 
NS 
NS 
0.041 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NSAID, n0n-steroidal nti-inflammatory drug; NS, not significant. 
Table II(b) 
Scores of the outcome measures at baseline--outcome easures evaluated by the assessor. The numbers 
are the mean visual analog scale scores ± S.E. The P values are for the intergroup comparisons 
P-value 
Hylan 
Hylan G=F 20+ Hylan G-F Hylan G-F Hylan G-F 20+ 
NSAID G-F 20 NSAID 20 vs 20+ NSAID NSAID vs 
Outcome measure (N= 33) (N= 29) (N= 34) NSAID vs NSAID hylan G-F 20 
Effusion 19 ± 3 16 + 3 14 ± 3 NS NS NS 
Medial joint tenderness 45 _+ 4 44 ± 4 37 ± 4 NS NS NS 
Lateral joint tenderness 36 ± 4 38 _+ 4 33 + 4 NS NS NS 
Pain while walking 57 +_ 4 53 ± 4 49 ± 4 NS NS NS 
Overall assessment 59 ± 3 55 ± 3 54 _+ 3 NS NS NS 
50 foot walk time 13 ± 1 13 ± 1 13 ± 1 NS NS NS 
NSAID, non-steroidal nti-inflammatory drug; NS, not significant. 
measures of the study. Over the 12-week course of 
study, the pat ients in all three t reatment  groups 
experienced improvements that  were both h ighly 
stat ist ical ly s ignif icantly different (P < 0.01) and 
cl inical ly important  by standardized cr i ter ia [37]. 
When compar ing the improvement scores among 
the three t reatment  groups, patients in the two 
hylan G-F 20 groups general ly improved more 
than the patients in the NSAID-only group. This was 
true for all outcome measures except activity 
restr ict ion, medial  tenderness and pain at night, 
However, this nominal ly  greater efficacy for the 
hy lan G-F 20 groups was usual ly not stat ist ical ly 
signif icantly different. The  only outcome measure 
to~show a statist ical ly s ign i f i cant  difference 
between the groups was pain at rest, for which the 
hy lan G-F 20-only group improved signif icantly 
more than  the NSAID-only group (P = 0.05). 
Fourteen patients in  the 'evaluable'  pat ient 
populat ion (15%) presented with a synovial  effusion 
greater than 2,0ml at the first int ra-art icu lar  
treatment,  Five were randomized to the NSAID-only  
group, seven to the hy lan G-F 20-only group and two 
to the hy lan G-F 20 + NSAID group, By the last 
t reatment  visit (week 4) a cl inical ly detectable 
effusion was absent in all but one of the patients, 
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Table III(a) 
Mean improvements at week 12 for the outcome measures evaluated by the patients and those evaluated by 
the blinded assessor. Al l  mean improvements were highly statistically significantly different from the 
baseline values (P < 0.01) 
Mean improvement 
NSAID Hylan G-F 20 Hylan G-F 20 + NSAID 
(N = 32) (N = 25) (N= 32) 
Outcome measure valuated by the patient 
Pain with motion 19 + 4 23 -+ 4 
Pain at rest 9 _+ 4 19 + 4 
Pain at night 13 + 4 21 -+ 5 
Restriction of activity 14 -+ 5 13 + 6 
Overall assessment of arthritic pain 19 _+ 5 24 + 5 
Outcome measure valuated by the assessor 
Medial joint tenderness ~ 14 + 4 19 +_ 4 
Lateral joint tenderness 9 _+ 4 17 -+ 5 
Pain while walking 19 +_ 4 27 + 5 
Overall assessment of clinical condition 16 _+ 3 24 _+ 4 
26.+4 
12.+4 
10_+4 
14_+5 
26-+4 
10_+4 
12.+4 
22_+4 
22.+3 
NSAID, non-steroidal nti-inflammatory drug. 
Table III(b) 
q-Statistical analysis of improvement a week 12, both those evaluated by the patient and 
those evaluated by the blinded assessor. The hylan G-F 20-only group (test group) is 
compared vs the non-steroidal anti-inflammatory drug (NSAID)-only group (control group). 
The q value is the ratio of the improvement from baseline of the group to the improvement 
from baseline of the control groups. The ql value is the ratio of the lower 95% confidence 
limit of the improvement from baseline of the test group to the improvement from baseline of 
the control group. This value represents minimum equivalent efficiency of hylan G-F 20 
therapy compared with NSAID therapy. See text for details 
q-Statistical values 
q 
(hylan G-F 20-only vs 
NSAID-only) 
ql 
(hylan G-F 20-only vs 
NSAID-only) 
Outcome measure valuated by patients 
Pain with motion 
Pain at rest 
Pain at night 
Restriction of activity 
Overall assessment of arthritic pain 
Outcome measure valuated by assessor 
Medial joint 
Tenderness 
Lateral joint 
Tenderness 
Pain while walking 
Overall assessment of clinical condition 
1.24 0.71 
2.26 1.19 
1.58 0.74 
0.89 < 0.01 
1.23 0.63 
1.36 0.68 
1.78 0.72 
1.44 0.89 
1.44 0.90 
NSAID, non-steroidal nti-inflammatory drug. 
who was in the hy lan G-F 20 + NSAID group. Thus, 
in this patient populat ion, synovial effusions 
resolved by the third arthrocentesis,  whether or not 
the patients were treated with cont inuous NSAID 
therapy or with v iscosupplementat ion with hylan 
G-F 20. Furthermore,  a separate statist ical analysis 
of efficacy for the patients with effusions demon- 
strated that they did as well cl inically as patients 
that  presented wi thout  an effusion (data not 
shown). 
ASSESSMENT OF EQUIVALENCY 
Because all the t reatments were effective at 12 
weeks, essential ly wi thout  any statist ical ly signifi- 
cant differences, it was necessary to analyze the  
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abil ity of the study to have detected a difference 
among the treatments.  One approach to this is to 
determine the  lower 95% conf idence- l imit  of the 
rat io of the least mean squared improvements from 
basel ine for the eff icacy variables of the test 
t reatment  o the control  t reatment.  This type of 
analysis, the so called q-statistical analysis, is one 
way suggested by U.S. regu latory  agencies to 
evaluate the therapeut ic  equivalence of s imilar 
pharmaceut ica l  gents [34]. A ql value (the lower 
conf idence l imit of the improvement ratio) of 0.6 is 
the minimal value that  can be considered to 
demonstrate therapeut ic  equivalence [34]. There- 
fore, q-statistical analysis was performed to 
determine whether  or not, with 95% confidence, the 
eff icacy of hylan-only t reatment  was greater  than 
or equal to the eff icacy of NSAID-only t reatment.  
The q values reported in Table III(b) are defined as 
the rat io of the least mean square improvement for 
the hylan-only group to that  for the NSAID-only 
group. The q values are >1 for every outcome 
measure except act ivity restr ict ion,  because the 
magnitude of improvement is greater  in the hylan 
G-F 20-only group. The last column of Table III lists 
the ql values. These are > 0.60 for all values except 
restr ict ion of activity. Thus, the hylan G-F 20-only 
and NSAID-only groups can be considered equival- 
ent, to a 95% confidence level, for all outcome 
measures except activity restr ict ion.  
FOLLOW-UP BETWEEN WEEKS 12 AND 26 
Pat ients were instructed to te lephone the 
invest igator if their  pain re turned to its pre-study 
level. None of the pat ients in the hy lan G-F 
20+NSAID group reported a re turn  of pain to 
pre-study levels, compared with five (16%) of the 
NSAID-only pat ients and seven (26%) of the hylan 
G-F 20-only patients. The super ior i ty  of the hylan 
G-F 20+NSAID group in this respect  was 
stat ist ical ly s ignif icant (P-- 0.019). 
Resumpt ion or d iscont inuat ion ofNSAID therapy  
was also moni tored between weeks 12 and 26. 
Only one pat ient  (3%) in the NSAID-only group 
discont inued NSAID therapy, compared to five 
(16%) of the hy lan G-F 20 + NSAID group, but this 
dif ference was not  stat ist ical ly signif icant: In the 
hy lan G-F 20-only group, 12 (44%) of the pat ients 
were able to completely refra in from NSAID therapy 
for the ent ire 26 weeks. This difference between the 
hy lan G-F 20-only group and the two NSAID groups 
was stat ist ical ly signif icant, but these dif ferences 
are at least part ia l ly  attr ibutable to the study 
design. 
26 WEEK FOLLOW-UP 
The longer term eff icacy of v iscosupplementat ion 
with hylan G-F 20 was assessed by a te lephone 
interview between the evaluator  and the pat ient  24 
weeks after the last ar throcentes is  or hy lan  G-F 20 
injection. Because the method of assessment at 26 
weeks differed from that  at baseline, improvement  
scores at week 26 could not  be calculated relat ive to 
the basel ine scores. The mean VAS scores at week 26 
for the three t reatment  groups are presented in 
Table IV. Only the pat ient-evaluated VAS variables 
were determined, because the eva luator  was 
judging the patient's percept ion of cl inical con- 
dition, rather  than  performing a persona l  evalu- 
ation. As was observed at the week 12 endpoint ,  both 
hy lan G-F 20 groups consistent ly showed bet ter  
scores than the NSAID-only group. But  in cont rast  
to the week 12 endpoints,  there were a number  of 
stat ist ical ly s ignif icant differences in the hy lan G-F 
20-only group vs the NSAID-only group, and for the 
hylan G-F 20 + NSAID group, stat ist ical ly signifi- 
cant super ior i ty  over the NSAID-only group was 
Table IV 
Mean visual analog scale scores at week 26 assessed by the follow-up telephone interview at 
week 26. The values are the means of the visual analog scale scores ± S.E. 
Outcome measure 
Hylan G-F 20+ 
NSAID Hylan G-F 20 NSAID 
(N= 31) (N= 27) (N = 32) 
Pain with motion 52 ± 4* 40 + 5 37 ± 4* 
Pain at rest 22 _+ 3* 25 +_ 3t 11 ± 3*t 
Pain at night 28 ± 4* 25 ± 5t 9 +_ 4*t 
Restriction of activity 52 _+ 5* 41 +_ 5 38 + 4 
Overall assessment of arthritic pain 52 + 4* 47 __4 37 ± 4 
*Indicates that the hylan G-F20+non-steroidal anti-inflammatory drug (NSAID) group was 
statistically significantly superior (P < 0.05) to the NSAID-only group in all the variables. 
tIndicates where comparisons between the hylan G-F 20 + NSAID group and the hylan G-F 20-only group 
were statistically significantly different (P < 0.05), i.e. pain at rest and pain at night. 
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Table V 
Patients who were 'symptom-free' at the week 26 follow-up telephone interview. Symptom-free was defined 
as a reduction of the patient's visual analog scale score to <20 mm 
Outcome measure 
Hylan G-F 20- 
NSAID-only only Hylan G-F 20 + NSAID 
N (%) N (%) N (%) 
Pain with motion 
Pain at rest 
Pain at night 
Restriction of activity 
Overall assessment of athritic pain 
2 (6%)*t 8 (30%)* 9 (28%)t 
15 (48%)t 13 (48%)$ 26 (81%)t$ 
15 (48%)t 17 (63%) 25 (81%)t 
3 (10%) 7 (26%) 8 (25%) 
3 (10%) 5 (19%) 8 (25%) 
*Indicates where comparisons between the hylan G-F 20-only group and the non-steriodal nti-inflammatory drug 
(NSAID)-only were statistically significantly different (P < 0.05). 
tIndicates where comparisons between hylan G-F 20 + NSAID group and the NSAID-only group were statistically 
significantly different (P < 0.05). 
:~Indicates where comparisons between the hylan G-F 20 +'NSAID group and the hylan G-F 20-only group were statistically 
significantly different (P < 0.05). 
found for every evaluat ion variable. Thus, when 
pain is measured 6 months  after  hy lan G-F 20 
administrat ion,  the eff icacy of v iscosupplementa-  
t ion with cont inuous NSAID therapy is stat ist ica l ly  
s ignif icantly bet ter  for var iables which did not  show 
any difference at 12 weeks. Rest pa in  and n ight  pain 
in the hy lan G-F 20+NSAID group were also 
signif icantly improved when compared  to the hy lan 
G-F 20-only group at week 26. These data suggest a 
long-term addit ive value for hy lan  G-F 20 viscosup- 
p lementat ion  when combined wi th  NSAID therapy. 
Table V presents  a categor ica l  analys is  of the 
percentage of pat ients  in each t reatment  group 
whose VAS scores were reduced to < 20 mm, which 
was defined as a ' symptom free' score. Again the two 
hy lan G-F 20 groups consistent ly  did better  than  the 
NSAID-only group, with pain wi th  mot ion  in the 
hy lan G-F 20-only group being s igni f icant ly better, 
and pain with motion,  pain at n ight  and rest  pain 
s igni f icant ly bet ter  in the hy lan  G-F 20 + NSAID 
group. 
F i f teen pat ients  in the hy lan  G-F 20-only group 
resumed tak ing  the i r  NSAID at some point  between 
weeks 12 and 26, and 12 were able to refrain 
complete ly  from NSAID use (Table VI). The protocol  
did not specif ical ly ins t ruct  the pat ients  with 
respect  o NSAID therapy after  the last  study visit 
(week 12). These two subgroups of the hy lan G-F 
20-only group were separate ly  evaluated and 
compared.  The hy lan G-F 20-only pat ients  who took 
no NSAIDs for the ent i re 26-week per iod were cal led 
'hy lan G-F 20-only-26', and the hy lan G-F 20-only 
pat ients  who resumed NSAID use between weeks 12 
and 26 were cal led 'hy lan G-F 20-only-12'. 
The 12 'hy lan G-F  20-only-26' pat ients,  i.e. those 
who were able to refrain complete ly  from NSAID 
therapy for the full 26-week period, had consistent ly  
bet ter  scores than  did the 15 'hy lan G-F 20-only-12' 
Table VI 
Outcome measures for the hylan G-F 20-only group--comparison between those who did or 
did not resume use of non-steriodal anti-inflammatory drugs (NSAIDs)  between weeks 12 
and 26. The mean visual analog scale measures + S.E. for the outcome measures assessed at 
the 26 week follow-up telephone interview for the patients who were randomized to the hylan 
G-F 20-only group, comparing the patients who resumed using an NSAID with those who 
did not 
Mean ± S.E. 
Hylan G-F 20-only-12 Hylan G-F 20-only-26 
Variables (N = 15) (N = 12) P-value 
Pain with motion 56 ± 5 21 ± 5 0.0001 
Pain at rest 30 _+ 5 19 ± 6 NS 
Pain at night 31 ± 8 17 ± 9 NS 
Restriction of activity 53 4- 6 25 ± 6 0.0029 
Overall pain 55 4- 6 37 4- 7 0.0468 
The 'hylan G-F 20-only-12' subset is the patients in the hylan G-F 20-only group who resumed NSAID 
therapy between weeks 12 and 26. The 'hylan G-F 20-only-26' subset is the patients in the G-F 20-only group 
who did not resume NSAID therapy between weeks 12 and 26. 
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patients, i.e. those who resumed NSAID use. For 
three of the five pain variables this difference was 
statistically significant despite the small group size 
(Table VI). Although this observation probably 
results, at least in part, from the fact that patients 
who resumed NSAIDs did so because they were 
experiencing increased pain, nevertheless 44% of 
the patients in the hylan G-F 20-only group were 
sufficiently improved for 6 months to refrain 
completely from taking NSAIDs, and many were 
improved to a level that they would be classified as 
'symptom-free' (< 20 on VAS). 
SAFETY 
Sixty-eight patients in the 'intent-to-treat' patient 
population received a total of 238 hylan G-F 20 
injections (with or without NSAIDs). One patient 
received a single injection, 55 received three 
injections and 12 received six injections. Adverse 
events were reported in the case report forms of only 
six patients. Three of these were unrelated to hylan 
G-F 20 injections: one patient was in the 
NSAID-only group, one patient had an accident- 
related lower back sprain and one patient had a 
whiplash resulting from an automobile accident. 
The remaining three patients had local and 
transient adverse vents in the injected knees; only 
one resulted in withdrawal from study. 
Two of the three local reactions observed after 
intra-articular injection of hylan G-F 20 that were 
attributable to the device were similar in their 
clinical presentation. Pain began within 24 h after 
injection, accompanied by warmth and effusion. 
The effusion was removed by arthrocentesis and 
analyzed for cells, crystals and microbiology. 
One of the synovial fluids was reported to have a 
high macr0phage count, but they were otherwise 
unremarkable. Both patients recovered within 
several days without seqUelae. The third adverse 
event was not reported until  several months after 
tl/e injections were completed and the temporal 
relationship between the injection and the onset 
of pain was not clear. The patient continued to 
receive intra-articular hylan G-F 20 and no effusion 
could be collected uring the arthrocenteses that 
preceded each subsequent two injections. Despite 
the patient's reported increase in pain, his VAS 
scores for pain decreased over the course of the 
three hylan G-F 20 injections. 
Discuss ion  
This clinical trial was designed to provide 
practical information on how hylan G-F 20 visco- 
supplementation fits into the medical armamentar- 
ium for treating OA of the knee. It addresses the 
clinically relevant question of how to treat patients 
with OA on NSAID therapy who are not achieving 
sufficient pain reduction. Furthermore, the study 
design enabled an evaluation of whether hylan G-F 
20 viscosupplementation ca prevent a flare in pain 
when NSAID therapy was discontinued. For these 
reasons the study was designed without a wash-out 
period and without a placebo control. The three 
study groups enable a direct comparison of 
patients on NSAIDs who either: (1) continue their 
medication; (2) discontinue their medication and 
replace it with three hylan G-F 20 injections; or 
(3) continue their medicatior~ and add three hylan 
G-F 20 injections to their therapeutic regimen. 
Patients in all three groups received arthrocenteses 
in order to control for the intra-articular injection 
and to maintain blindness. 
The results of this study support he hypothesis 
that treatment of the pain of OA of the knee with 
hylan G-F 20 is at least as effective as treatment with 
NSAIDs. Furthermore, the patients discontinued 
from NSAIDs did not flare when they were treated 
with hylan G-F 20 viscosupplementation. The 
patients improved with all treatments, but among 
their responses only a few of the differences were 
statistically significant, all in favor of hylan G-F 20, 
but these differences were of small magnitude 
and would not likely be clinically meaningful. 
The question of whether or not a significant 
difference was missed (type II error) was addressed 
by analyzing the data for equivalence. The result 
of this analysis showed that the response with 
hylan G-F 20 alone was, at the 95% confidence 
level, at least 60% as efficacious as that of the 
NSAID-treated groups. This is the level that is 
conventionally accepted as indicating pharma- 
ceutical equivalence [34]. 
It is interesting to note that there was an 
increased response to NSAIDs, despite the absence 
of a wash-out phase. Several factors may contribute 
to this response. First, participation in the 
trial itself may have a placebo effect. Second, the 
patients may also have responded to arthrocentesis. 
Finally, these improvements may also reflect the 
natural cycle of flare and remission that character- 
izes pain of OA. However, irrespective of the cause, 
there is no reason to suspect hat the response was 
due to a factor that differs among the treatment 
groups. 
The study was not designed to and cannot answer 
the question of whether or not there was a 
synergistic effect. If there were, the magnitude 
would have to be small. Likewise, there is no 
suggestion whatsoever of any antagonistic influ- 
ences between hylan G-F 20 and NSAIDs. 
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Data obtained by te lephone interv iew 26 weeks 
after the three hylan G-F 20 in ject ions demonst rate  
some" statist ical ly s ignif icant differences between 
these three alternat ive treatments.  The hylan G-F 20 
and NSAID group showed signif icantly less 
pain than the NSAID-only group for all of the key 
outcome measures. Even the hy lan G-F 20-only 
group showed signif icantly less pain on mot ion 
when the week 26 data were analyzed categor ical ly 
(data not shown). Thus, there appear to be som~ 
benefits emerg ing 6 months after pat ients are 
t reated with hylan G-F 20, despite their  being l itt le 
if any measurable benefit  over NSAID therapy at 3 
months after hy lan G-F 20 injection. 
One of the most important  aspects of viscosupple- 
mentat ion compared with therapy with analgesics 
or NSAIDs is that  its analgesic effect lasts for 
• months after the intra-art icular ly  in jected viscosup- 
p lementat ion product  has cleared the jo int  and the 
body. Studies on animals and humans clearly 
showed that in jected exogenous hya luronan and 
hylan G-F 20 is completely removed from the joint 
and the body with in 7-14 days [38, 39]. Yet, as this 
study showed, 44% of the hylan G-F 20-only t reated 
patients showed signif icant improvement after 
6 months, wi thout  any concomitant  herapeut ic  
intervention. 
The indicat ion for t reatment  with hylan G-F 20 is 
to relieve the pain of OA of the knee and in that  it 
was shown to be as effective as cont inuous NSAID 
therapy. This trial,  in the t ime frame of the 12 weeks 
of the study and the 26 week follow-up, can not, of 
course, address the issues of 'chondroprotect ion'  or 
'chondrodestruct ion' ,  i.e. whether  or not the 
t reatment  affects the rate of change in the st ructura l  
deter iorat ion of the joint. Nevertheless, if the pain 
rel ief afforded by the therapy allows normal,  but not 
excessive, jo int use, one might expect at least a 
beneficial physiological  response. It could also 
confer extra benefit to the pat ient  by al lowing 
const i tut ional  exercise wi thout  gastric, hepatic and 
renal  toxicity, or other  systemic side-effects of the 
NSAIDs. 
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